HC Wainwright Has Positive Forecast for EPRX FY2026 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Equities research analysts at HC Wainwright increased their FY2026 earnings per share estimates for Eupraxia Pharmaceuticals in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.96) per share for the year, up from their prior estimate of ($0.98). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.23) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at $0.14 EPS.

Other equities analysts have also issued reports about the stock. Royal Bank Of Canada started coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $14.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 15th. Oppenheimer reaffirmed an “outperform” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. Finally, Wedbush assumed coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Eupraxia Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ EPRX opened at $7.81 on Friday. The business’s 50 day moving average price is $7.63 and its 200 day moving average price is $7.25. Eupraxia Pharmaceuticals has a 52 week low of $5.63 and a 52 week high of $9.32. The company has a current ratio of 12.25, a quick ratio of 16.00 and a debt-to-equity ratio of 0.03.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.03.

Institutional Trading of Eupraxia Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its holdings in Eupraxia Pharmaceuticals by 28.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $133,000 after acquiring an additional 3,500 shares during the period. Persistent Asset Partners Ltd purchased a new position in Eupraxia Pharmaceuticals during the second quarter valued at approximately $25,000. AXQ Capital LP lifted its holdings in Eupraxia Pharmaceuticals by 34.2% in the second quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock valued at $140,000 after acquiring an additional 5,390 shares during the period. BlackRock Inc. acquired a new position in Eupraxia Pharmaceuticals in the second quarter valued at approximately $40,000. Finally, Ingalls & Snyder LLC lifted its holdings in Eupraxia Pharmaceuticals by 10.2% in the third quarter. Ingalls & Snyder LLC now owns 75,450 shares of the company’s stock valued at $687,000 after acquiring an additional 7,000 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.